The trend continues in which big-name venture investors band together to back new companies with an experimental medicine developed by another biotech.
June 18, 2026 09:40 AM EDTUpdated 04:34 PM
FinancingStartups
RA, Forbion and Sanofi Ventures appear to back new eye drug from Korea
Kyle LaHucik
Biotech Correspondent
[Bio USA] Korean biotechs bolster AstraZeneca partnership
AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion | Fortune
Nortiva purrs into action with long-acting Lynx platform salvaged from Langer startup
Biogen adds more immune drugs in $1B buyout of secretive startup Raythera
Another big deal, another sign biotech M&A is back
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
Cambrian's experimental longevity drug mimics exercise
Bionyra brings in $165M for next-generation immune drugs
San Francisco biotech Osanni Bio, looking to build out a suite of ophthalmology- and cardiology-focused
SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund
SAN DIEGO — Korean biotechnology firms have advanced their partnerships with AstraZeneca, bolstering efforts toward open…
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check…
“We want to be the SpaceX of the pharmaceutical industry,” Alex Zhavoronkov, co-CEO of Insilico Medicine tells Fortune.
Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin…
